CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.9171
2.12%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0205
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Homology Medicines Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.8981
Open* 0.8971
1-Year Change* -0.23%
Day's Range* 0.8971 - 0.9671
52 wk Range 0.46-1.76
Average Volume (10 days) 209.20K
Average Volume (3 months) 7.05M
Market Cap 33.46M
P/E Ratio -100.00K
Shares Outstanding 57.93M
Revenue 1.96M
EPS -2.27
Dividend (Yield %) N/A
Beta -0.16
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 25, 2024 0.9171 0.0199 2.22% 0.8972 0.9695 0.8971
Mar 22, 2024 0.8981 0.0294 3.38% 0.8687 0.9321 0.8537
Mar 21, 2024 0.8819 0.0138 1.59% 0.8681 0.8922 0.8671
Mar 20, 2024 0.8931 0.0145 1.65% 0.8786 0.9170 0.8571
Mar 19, 2024 0.8973 -0.0098 -1.08% 0.9071 0.9322 0.8783
Mar 18, 2024 0.8973 0.0002 0.02% 0.8971 0.9021 0.8651
Mar 15, 2024 0.9171 0.0000 0.00% 0.9171 0.9251 0.9071
Mar 14, 2024 0.9171 0.0100 1.10% 0.9071 0.9501 0.9071
Mar 13, 2024 0.9071 0.0300 3.42% 0.8771 0.9071 0.8771
Mar 12, 2024 0.8946 0.0175 2.00% 0.8771 0.8971 0.8771
Mar 11, 2024 0.9069 0.0298 3.40% 0.8771 0.9069 0.8771
Mar 8, 2024 0.8869 -0.0003 -0.03% 0.8872 0.8981 0.8771
Mar 7, 2024 0.8995 -0.0070 -0.77% 0.9065 0.9071 0.8471
Mar 6, 2024 0.8971 0.0300 3.46% 0.8671 0.8971 0.8671
Mar 5, 2024 0.8669 -0.0102 -1.16% 0.8771 0.8874 0.8585
Mar 4, 2024 0.8917 -0.0083 -0.92% 0.9000 0.9000 0.8640
Mar 1, 2024 0.8931 -0.0369 -3.97% 0.9300 0.9400 0.8800
Feb 29, 2024 0.9200 0.0189 2.10% 0.9011 0.9300 0.8828
Feb 28, 2024 0.9200 0.0013 0.14% 0.9187 0.9348 0.8960
Feb 27, 2024 0.9150 0.0230 2.58% 0.8920 0.9194 0.8700

Q32 Bio Inc Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3.208 33.971 2.702 1.666 5.322
Revenue 3.208 33.971 2.702 1.666 5.322
Total Operating Expense 5.24 129.92 132.965 111.609 65.248
Selling/General/Admin. Expenses, Total 38.138 36.835 32.573 22.211 17.3
Research & Development 98.351 93.085 100.392 89.398 47.948
Operating Income -2.032 -95.949 -130.263 -109.943 -59.926
Interest Income (Expense), Net Non-Operating 3.23 0.185 1.569 6.027 4.349
Other, Net
Net Income Before Taxes 1.198 -95.764 -128.694 -103.916 -55.577
Net Income After Taxes 0.483 -95.764 -128.694 -103.916 -55.577
Net Income Before Extra. Items -5.005 -95.764 -128.694 -103.916 -55.577
Net Income -5.005 -95.764 -128.694 -103.916 -55.577
Income Available to Common Excl. Extra. Items -5.005 -95.764 -128.694 -103.916 -55.577
Income Available to Common Incl. Extra. Items -5.005 -95.764 -128.694 -103.916 -55.577
Diluted Net Income -5.005 -95.764 -128.694 -103.916 -55.577
Diluted Weighted Average Shares 57.3998 55.2833 45.9108 42.1177 28.5518
Diluted EPS Excluding Extraordinary Items -0.0872 -1.73224 -2.80313 -2.46728 -1.94653
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -1.57347 -1.73224 -2.80313 -2.46728 -1.94653
Unusual Expense (Income) -131.249
Equity In Affiliates -5.488
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.354 0.802 0.802 0.802 0.802
Revenue 0.354 0.802 0.802 0.802 0.802
Total Operating Expense 31.17 28.313 35.296 33.664 29.109
Selling/General/Admin. Expenses, Total 8.188 8.325 8.147 7.81 8.034
Research & Development 22.982 19.988 27.149 25.854 21.075
Operating Income -30.816 -27.511 -34.494 -32.862 -28.307
Interest Income (Expense), Net Non-Operating 1.511 1.469 1.455 1.269 0.474
Net Income Before Taxes -29.305 -26.042 -33.039 -31.593 -27.833
Net Income After Taxes -29.305 -26.042 -32.938 -31.547 -27.728
Net Income Before Extra. Items -35.044 -28.844 -34.295 -33.726 -29.089
Net Income -35.044 -28.844 -34.295 -33.726 -29.089
Income Available to Common Excl. Extra. Items -35.044 -28.844 -34.295 -33.726 -29.089
Income Available to Common Incl. Extra. Items -35.044 -28.844 -34.295 -33.726 -29.089
Diluted Net Income -35.044 -28.844 -34.295 -33.726 -29.089
Diluted Weighted Average Shares 57.7953 57.7163 57.4818 57.4472 57.3856
Diluted EPS Excluding Extraordinary Items -0.60635 -0.49975 -0.59662 -0.58708 -0.5069
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.60635 -0.49975 -0.59662 -0.58708 -0.5069
Unusual Expense (Income) 0 0 0 0 0
Equity In Affiliates -5.739 -2.802 -1.357 -2.179 -1.361
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 181.015 191.909 219.564 266.577 221.685
Cash and Short Term Investments 175.026 155.873 217.431 262.388 214.737
Cash 0.019 0.059 0.25 0.25 0.471
Cash & Equivalents 33.967 108.323 217.181 39.524 31.74
Short Term Investments 141.04 47.491 0 222.614 182.526
Prepaid Expenses 5.989 7.129 2.133 4.189 6.948
Other Current Assets, Total 28.907
Total Assets 228.47 211.721 263.737 310.567 259.094
Property/Plant/Equipment, Total - Net 21.641 17.859 42.899 42.716 35.637
Property/Plant/Equipment, Total - Gross 27.877 23.705 59.274 51.126 37.745
Accumulated Depreciation, Total -6.236 -5.846 -16.375 -8.41 -2.108
Other Long Term Assets, Total 0 1.953 1.274 1.274 1.772
Total Current Liabilities 22.576 17.226 22.658 12.374 22.519
Accounts Payable 1.144 2.366 4.722 2.608 15.732
Accrued Expenses 20.276 11.652 12.304 7.644 5.04
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.156 3.208 5.632 2.122 1.747
Total Liabilities 50.492 42.07 67.742 52.06 62.739
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 27.916 24.844 45.084 39.686 40.22
Total Equity 177.978 169.651 195.995 258.507 196.355
Preferred Stock - Non Redeemable, Net
Common Stock 0.006 0.006 0.005 0.004 0.003
Additional Paid-In Capital 607.513 593.784 524.358 457.994 292.187
Retained Earnings (Accumulated Deficit) -429.137 -424.132 -328.368 -199.674 -95.758
Unrealized Gain (Loss) -0.404 -0.007 0.183 -0.077
Total Liabilities & Shareholders’ Equity 228.47 211.721 263.737 310.567 259.094
Total Common Shares Outstanding 57.4839 57.1503 50.2656 45.1167 37.3585
Long Term Investments 25.814
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 106.635 131.336 153.583 181.015 213.204
Cash and Short Term Investments 103.298 127.071 150.025 175.026 201.074
Cash & Equivalents 29.111 76.797 39.454 33.986 43.162
Short Term Investments 74.187 50.274 110.571 141.04 157.912
Prepaid Expenses 3.023 4.265 3.558 5.989 12.13
Total Assets 140.063 169.337 197.881 228.47 262.651
Property/Plant/Equipment, Total - Net 19.471 20.682 21.262 21.641 22.315
Property/Plant/Equipment, Total - Gross 19.471 27.275 27.638 27.877 29.158
Accumulated Depreciation, Total 0 -6.593 -6.376 -6.236 -6.843
Other Long Term Assets, Total 0 0
Total Current Liabilities 25.292 22.939 18.507 22.576 25.252
Accounts Payable 7.803 3.393 3.635 1.144 4.835
Accrued Expenses 17.489 19.546 14.518 20.276 18.459
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0 0.354 1.156 1.958
Total Liabilities 51.852 49.962 45.982 50.492 53.59
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 26.56 27.023 27.475 27.916 28.338
Total Equity 88.211 119.375 151.899 177.978 209.061
Common Stock 0.006 0.006 0.006 0.006 0.006
Additional Paid-In Capital 614.22 612.482 610.056 607.513 604.354
Retained Earnings (Accumulated Deficit) -525.979 -493.025 -457.981 -429.137 -394.842
Unrealized Gain (Loss) -0.036 -0.088 -0.182 -0.404 -0.457
Total Liabilities & Shareholders’ Equity 140.063 169.337 197.881 228.47 262.651
Total Common Shares Outstanding 57.9022 57.7981 57.7948 57.4839 57.4806
Other Current Assets, Total 0.314 0
Long Term Investments 13.957 17.319 23.036 25.814 27.132
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -5.005 -95.764 -128.694 -103.916 -57.215
Cash From Operating Activities -113.661 -109.751 -94.332 -91.358 -42.562
Cash From Operating Activities 1.293 8.353 7.965 6.318 1.289
Non-Cash Items -113.299 19.463 14.877 5.777 1.161
Changes in Working Capital 3.35 -41.803 11.52 0.463 12.203
Cash From Investing Activities 36.716 -50.788 204.896 -51.799 -121.787
Capital Expenditures -1.285 -2.396 -3.733 -21.833 -24.939
Other Investing Cash Flow Items, Total 38.001 -48.392 208.629 -29.966 -96.848
Cash From Financing Activities 0.596 52.169 53.093 158.213 150.994
Issuance (Retirement) of Stock, Net 0.596 52.169 53.093 158.213 150.994
Net Change in Cash -76.349 -108.37 163.657 15.056 -13.355
Cash Taxes Paid 0.72
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -28.844 -5.005 29.29 63.016 92.105
Cash From Operating Activities -26.054 -113.661 -86.462 -61.53 -30.684
Cash From Operating Activities 0.225 1.293 0.997 0.676 0.348
Non-Cash Items 4.635 -113.299 -117.056 -121.539 -126.372
Changes in Working Capital -2.07 3.35 0.307 -3.683 3.235
Cash From Investing Activities 31.372 36.716 18.725 126.943 168.312
Capital Expenditures -0.228 -1.285 -1.276 -1.27 -1.149
Other Investing Cash Flow Items, Total 31.6 38.001 20.001 128.213 169.461
Cash From Financing Activities 0.15 0.596 0.564 0.44 0.44
Issuance (Retirement) of Stock, Net 0.15 0.596 0.564 0.44 0.44
Net Change in Cash 5.468 -76.349 -67.173 65.853 138.068

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Homology Medicines Company profile

About Homology Medicines Inc

Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company focuses on patients suffering from rare genetic diseases by curing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo either through gene therapy or nuclease-free gene editing across a range of genetic disorders. Its various set of AAVHSCs allows it to target, via a single injection, a range of disease-relevant tissues, including the liver, central nervous system (CNS), peripheral nervous system (PNS), bone marrow, muscle and eye. Its lead product candidate, HMI-102, is a gene therapy for the treatment of adults with phenylketonuria (PKU). Its other gene therapy product development candidates for the treatment of lysosomal storage diseases are HMI-203, for the treatment of mucopolysaccharidosis type II (MPS II) and HMI-202.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Homology Medicines Inc revenues increased from $1.7M to $33.2M. Net loss decreased 37% to $62.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $63.1M (expense), General and administrative - Balancing decrease of 1% to $19.8M (expense).

Industry: Bio Therapeutic Drugs

1 Patriots Park
BEDFORD
MASSACHUSETTS 01730-2343
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

Gold

2,389.89 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0108%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.50 Price
-1.060% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

64,297.45 Price
+1.240% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

17,205.50 Price
-0.770% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading